Myrtelle, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 2020-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.myrtellegtx.com
Clinical Trials
1
Active:0
Completed:0
Trial Phases
1 Phases
Phase 1:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials
Phase 1
1 (100.0%)rAAV-Olig001-ASPA Gene Therapy for Treatment of Children With Typical Canavan Disease
Phase 1
Recruiting
- Conditions
- Canavan Disease
- Interventions
- First Posted Date
- 2021-04-06
- Last Posted Date
- 2025-01-09
- Lead Sponsor
- Myrtelle Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT04833907
- Locations
- 🇺🇸
Dayton Children's Hospital, Dayton, Ohio, United States
News
Myrtelle to Share First-Year Insights from FDA's START Pilot Program for Rare Disease Therapies at ASGCT 2025
Myrtelle Inc. will present at ASGCT's Annual Meeting on May 15, 2025, highlighting its experience as one of only three gene therapy developers selected for the FDA's START Pilot Program.